Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
MAGNEVIST is an injectable small-molecule contrast agent approved by the FDA in 1988 for use in diagnostic imaging. The product is used to enhance MRI images by improving visualization of internal body structures. It is administered via injection to patients undergoing magnetic resonance imaging procedures.
As a mature product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely focused on lifecycle management and defending market share rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Gadobutrol Magnevist-controlled Body Study
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Magnevist Post-marketing Surveillance in Japan
Multihance Versus Magnevist in Breast MRI
Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Magnetic Resonance Angiography
Worked on MAGNEVIST at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
With zero linked job openings and an approaching loss of exclusivity, MAGNEVIST represents a mature, stable but declining career opportunity. Roles on this product are primarily defensive and focused on market maintenance rather than growth or innovation.